Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

China Shineway Pharmaceutical Group Ltd ADR

Healthcare US CSWYY

19.25USD
0.00(0%)

Last update at 2026-06-18T13:30:00Z

Day Range

19.2519.25
LowHigh

52 Week Range

17.2722.54
LowHigh

Fundamentals

  • Previous Close 19.25
  • Market Cap727.07M
  • Volume0
  • P/E Ratio6.23
  • Dividend Yield2.44%
  • EBITDA737.52M
  • Revenue TTM3135.42M
  • Revenue Per Share TTM83.02
  • Gross Profit TTM 2266.21M
  • Diluted EPS TTM3.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1234.68M 1145.72M 1240.25M 917.02M 720.10M
Minority interest - - - - -
Net income 924.07M 840.05M 969.51M 722.77M 556.67M
Selling general administrative - 291.32M 326.50M 2098.46M 1756.24M
Selling and marketing expenses - 1597.31M 1981.62M - -
Gross profit 2204.46M 2831.75M 3394.12M 2938.31M 2410.34M
Reconciled depreciation - 68.73M 177.10M 185.86M 182.39M
Ebit 663.48M 1151.85M 1242.99M 713.58M 534.37M
Ebitda 732.44M 1220.59M 1420.09M 1103.52M 903.74M
Depreciation and amortization 68.95M 68.73M 177.10M - -
Non operating income net other - - - - -
Operating income 663.48M 842.60M 975.53M 722.40M 541.39M
Other operating expenses 2386.51M 2935.44M 3379.06M - -
Interest expense 5.53M 6.13M 2.74M 0.63M 1.25M
Tax provision - 305.67M 270.74M 194.25M 163.43M
Interest income - 176.72M 95.21M 92.43M 95.07M
Net interest income - 170.59M 92.47M 91.80M 93.81M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 310.62M 305.67M 270.74M 194.25M 163.43M
Total revenue 3049.99M 3778.04M 4516.54M 3950.64M 3223.55M
Total operating expenses 1540.98M 1989.15M 2418.58M 3228.23M 2682.16M
Cost of revenue 845.53M 946.29M 1122.42M 1012.32M 813.21M
Total other income expense net 571.20M 303.12M 264.72M - -
Discontinued operations - - - - -
Net income from continuing ops - 840.05M 969.51M 722.77M 556.67M
Net income applicable to common shares - - - 722.77M 556.67M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 10783.99M 10041.53M 9573.99M 8231.86M 7203.96M
Intangible assets 15.73M 23.32M 32.79M 47.35M 66.43M
Earning assets - - - - -
Other current assets 47.19M 93.28M 87.88M 32.01M 35.06M
Total liab 2717.05M 2574.63M 2539.22M 1849.34M 1302.48M
Total stockholder equity 8066.94M 7466.90M 7034.77M 6382.53M 5901.48M
Deferred long term liab - - - - -
Other current liab 1615.29M 1624.49M 1505.79M 493.55M 378.95M
Common stock 87.72M 87.66M 87.66M 87.66M 87.66M
Capital stock - 87.66M 87.66M 87.66M 87.66M
Retained earnings - 6726.44M 6326.28M 6367.61M 5879.00M
Other liab - - - 182.83M 196.78M
Good will 166.06M 165.96M 165.96M 165.96M 165.96M
Other assets 0.00001M - -7004.91330M 19.22M 20.46M
Cash 7193.62M 6140.15M 5888.78M 5026.27M 4205.72M
Cash and equivalents - - - - -
Total current liabilities 2511.87M 2450.00M 2433.72M 1665.59M 1098.37M
Current deferred revenue 222.00M - 17.96M - -
Net debt -6858.50178M -5793.62600M -5587.45000M - -
Short term debt 334.33M 338.27M 300.97M - -
Short long term debt - 330.00M 300.00M - 0.00000M
Short long term debt total 335.11M 346.53M 301.33M - -
Other stockholder equity 7979.22M 652.81M 620.82M -494.89100M -487.32000M
Property plant equipment - - - 1216.94M 1252.00M
Total current assets 9310.15M 8598.52M 8154.73M 6782.40M 5699.11M
Long term investments - - - - -
Net tangible assets - - - 6169.22M 5669.10M
Short term investments 376.88M 350.02M 20.00M 20.23M -
Net receivables 1000.72M 1201.88M 1260.37M 1042.54M 866.05M
Long term debt - - - - -
Inventory 691.74M 813.19M 897.71M 657.66M 587.96M
Accounts payable 340.24M 402.96M 484.79M 308.75M 228.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 97.79M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 4.62M - -
Deferred long term asset charges - - - - -
Non current assets total 1473.84M 1443.01M 1419.26M 1449.46M 1504.85M
Capital lease obligations - 16.53M 1.33M 7.44M 14.91M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -272.11000M -49.54000M 6.67M 8.74M 43.91M
Change to liabilities - - 147.36M 73.60M -4.66700M
Total cashflows from investing activities -272.11000M -49.54000M -45.42000M 395.01M -305.59100M
Net borrowings 30.00M 300.00M -7.68000M -378.03300M -34.88500M
Total cash from financing activities -392.47500M -26.73800M -250.03800M -828.93500M -329.78800M
Change to operating activities - - 370.99M 176.71M 148.20M
Net income 1145.72M 1240.25M 722.77M 556.67M 295.03M
Change in cash 251.38M 862.51M 820.54M 262.71M -2.99600M
Begin period cash flow 5888.78M 5026.27M 4205.72M 3943.01M 3946.01M
End period cash flow 6140.15M 5888.78M 5026.27M 4205.72M 3943.01M
Total cash from operating activities 963.13M 932.63M 1109.68M 703.15M 638.57M
Issuance of capital stock - - 0.00000M 3.66M 36.44M
Depreciation 68.73M 177.10M 185.86M 182.39M 208.41M
Other cashflows from investing activities 183.05M 84.25M 73.88M 388.92M -172.53400M
Dividends paid 407.92M 317.27M 241.73M 453.07M 173.56M
Change to inventory 169.97M -240.05000M -69.70300M -140.13200M -12.19600M
Change to account receivables 51.76M -290.74500M -158.70700M -66.96600M -93.26400M
Sale purchase of stock - - - - -
Other cashflows from financing activities -14.55900M -9.47000M -0.63000M -1.49300M -16.99400M
Change to netincome - - -88.90100M -79.12000M 97.05M
Capital expenditures 140.11M 144.32M 129.46M 93.63M 66.03M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 221.96M -93.61600M 289.94M 43.21M 38.07M
Stock based compensation - - 0.00000M 0.03M 0.13M
Other non cash items -473.28000M -391.10400M -122.20700M -118.94500M -79.72600M
Free cash flow 823.02M 788.31M 980.21M 609.52M 572.54M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CSWYY
China Shineway Pharmaceutical Group Ltd ADR		 - -% 19.25 6.23 163.93 0.23 0.68 0.03 0.09
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.

China Shineway Pharmaceutical Group Ltd ADR

No. 168, Shiluan Street, Shijiazhuang, China, 051430

Key Executives

Name Title Year Born
Mr. Zhenjiang Li Co-Founder & Exec. Chairman 1955
Ms. Yunxia Xin Co-Founder & Exec. Director 1963
Mr. Huimin Li Exec. Director 1968
Mr. Bun Ching Lee Financial Controller & Company Sec. 1973
Mr. King Kuen Hung Director of Investor Relation 1966
Mr. Yudong Zhang Gen. Mang. of Sales & Marketing 1974
Mr. Tiejun Liu Exec. Director 1974
Mr. Zhenjiang Li Co-Founder & Executive Chairman 1955
Ms. Yunxia Xin Co-Founder & Executive Director 1963
Mr. Huimin Li Executive Director 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.